Almdal TP, Heindorff H, Bardram L, Vilstrup H
They are pharmacy-prepared formulations using the active pharmaceutical ingredient, but they are not FDA-approved, have not been evaluated for bioequivalence, and may differ in formulation, concentration, and composition
doi:10.1056/NEJMoa2416394 37
If your body can't tolerate one GLP-1 drug, you may be able to try another
Following the results of the SELECT trial, the FDA approved a new indication for Wegovy (semaglutide) in March 2024: to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight
These myths can lead to poor decision-making, unnecessary medication changes, or avoidable suffering